Scribd
Upload
181 views

SK Mankind Pharma IPO PDF 200423

Mankind Pharma Limited, India's fourth largest pharmaceutical company, is issuing an IPO to raise ₹4,326 crores from April 25-27, 2022. The company develops and markets pharmaceutical and consumer healthcare products with a focus on the domestic Indian market. It has established brands in categories like condoms, pregnancy detection kits, and emergency contraceptives, and is the leader in male condoms, pregnancy detection kits, and emergency contraceptives in India. The IPO will be split with 50% for qualified institutional buyers, 15% for non-institutional investors, and 35% for retail investors.

Uploaded by

Shirish Umadi
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
181 views

SK Mankind Pharma IPO PDF 200423

Mankind Pharma Limited, India's fourth largest pharmaceutical company, is issuing an IPO to raise ₹4,326 crores from April 25-27, 2022. The company develops and markets pharmaceutical and consumer healthcare products with a focus on the domestic Indian market. It has established brands in categories like condoms, pregnancy detection kits, and emergency contraceptives, and is the leader in male condoms, pregnancy detection kits, and emergency contraceptives in India. The IPO will be split with 50% for qualified institutional buyers, 15% for non-institutional investors, and 35% for retail investors.

Uploaded by

Shirish Umadi
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 1

Mankind Pharma Limited IPO

April 25 to April 27

Mankind Pharma Limited is coming out with a fresh public issue to raise ₹ 4,326 crores
from the market.

Key details of the issue:


• Issue opens – April 25 (Tuesday)
• Issue closes – April 27 (Thursday)
• Issue size – ₹ 4,326 crores
• Price band – ₹ 1026 – 1080 per equity share
• Bid lot – 13 shares and in multiples thereof

And here are some details of the company and further details on the Mankind Pharma
Limited IPO issue.

Company details:
• Mankind Pharma Limited are India’s fourth largest pharmaceutical company in terms of
Domestic Sales and third largest in terms of sales volume for MAT December 2022 (Source:
IQVIA Dataset, IQVIA TSA MAT December 2022 Dataset for India (For FY20-22)). They are
engaged in developing, manufacturing and marketing a diverse range of pharmaceutical
formulations across various acute and chronic therapeutic areas, as well as several consumer
healthcare products. They are focused on the domestic market, as a result of which their
revenue from operations in India contributed to 97.60% of their total revenue from operations
for the Financial Year 2022, which was one of the highest among peers identified by IQVIA.

• They have primarily grown organically and are the youngest company among the five
largest pharmaceutical companies in India, in terms of Domestic Sales in 2022 (Source: IQVIA
Dataset, Annual filings / company data). They operate at the intersection of the Indian
pharmaceutical formulations and consumer healthcare sectors with the aim of providing
quality products at affordable prices, and have an established track record of building and
scaling brands in-house.

• They have created 36 brands in their pharmaceutical business They have one of the largest
distribution networks of medical representatives in the Indian pharmaceutical market (“IPM”)
and over 80% of doctors in India prescribed their formulations for MAT December 2022
(Source: IQVIA Dataset, annual filings by respective companies with stock exchanges, IQVIA
Medical Audit MAT Dec 2022 for MAT Mar'20-22 and MAT Dec’22).

• They are present in several acute and chronic therapeutic areas in India, including
anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS,
vitamins/minerals/nutrients and respiratory. They entered the consumer healthcare industry in
2007 and have since established several differentiated brands in the condoms, pregnancy
detection, emergency contraceptives, antacid powders, vitamin and mineral supplements
and anti-acne preparations categories.

• They are the category leaders in (i) the male condom category, where their Manforce brand
had Domestic Sales of approximately ₹4,616 million (representing a market share of
approximately 29.6%), (ii) the pregnancy detection kit category, where their Prega News
brand had Domestic Sales of approximately ₹1,844 million (representing a market share of
approximately 79.7%), and (iii) the emergency contraceptives category, where their
Unwanted-72 brand had Domestic Sales of approximately ₹1,083 million (representing a
market share of approximately 61.7%), for MAT December 2022.

Issue size: ₹ 4,326 crores


Issue break-up:
• QIB – 50% of the offer – ₹ 2163.18 crores
• NIB – 15% of the offer – ₹ 648.95 crores
• RET – 35% of the offer – ₹ 1514.22 crores

Listing: NSE and BSE

Registrar: KFin Technologies Limited

UPI: All retail applications through brokers are compulsorily in UPI mode.

Not a Sharekhan customer?


Not a Sharekhan customer, but still want to apply for the Mankind Pharma Limited IPO?
Become a Sharekhan customer in just 15 mins* by tapping here and take it from there!
(* T&C apply)

You might also like

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy